Given the strong demand for prenatal vitamins and Church & Dwight's solid Q2 performance, I believe CHD is currently overvalued amid rising costs and ...
Read
More
Given the strong demand for prenatal vitamins and Church & Dwight's solid Q2 performance, I believe CHD is currently overvalued amid rising costs and competitive pressures, making it a suitable candidate for a short position.